582 related articles for article (PubMed ID: 26725905)
1. The prognosis and management of inactive HBV carriers.
Invernizzi F; Viganò M; Grossi G; Lampertico P
Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905
[TBL] [Abstract][Full Text] [Related]
2. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers.
Park H; Lee JM; Seo JH; Kim HS; Ahn SH; Kim DY; Han KH; Chon CY; Park JY
Liver Int; 2012 May; 32(5):796-802. PubMed ID: 22128792
[TBL] [Abstract][Full Text] [Related]
4. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
[TBL] [Abstract][Full Text] [Related]
6. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels.
Nakazawa T; Shibuya A; Takeuchi A; Shibata Y; Hidaka H; Okuwaki Y; Takada J; Tanaka Y; Watanabe M; Minamino T; Sakurai K; Koizumi W
J Viral Hepat; 2011 Jul; 18(7):e191-9. PubMed ID: 21692932
[TBL] [Abstract][Full Text] [Related]
7. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B inactive carriers: clinical course and outcomes.
Tong MJ; Trieu J
J Dig Dis; 2013 Jun; 14(6):311-7. PubMed ID: 23433008
[TBL] [Abstract][Full Text] [Related]
9. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
[TBL] [Abstract][Full Text] [Related]
10. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
11. Role of hepatitis B surface antigen (HBsAg) in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus.
Yim SY; Um SH; Jung JY; Seo YS; Yim HJ; Ryu HS; Chun HJ; Jeen YT; Kim CD; Keum B; Lee HS
J Clin Gastroenterol; 2014 Feb; 48(2):166-71. PubMed ID: 24045280
[TBL] [Abstract][Full Text] [Related]
12. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
[TBL] [Abstract][Full Text] [Related]
13. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
14. [The follow-up of serum aminotransferase levels and investigation of hepatitis B virus load in inactive HBsAg carriers].
Olut AI; Ozünlü H; Bozdağ H; Ozkalay N
Mikrobiyol Bul; 2007 Jul; 41(3):429-33. PubMed ID: 17933254
[TBL] [Abstract][Full Text] [Related]
15. HBV: Do I treat my immunotolerant patients?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2016 Jan; 36 Suppl 1():93-9. PubMed ID: 26725904
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
17. A combination of different diagnostic tools allows identification of inactive hepatitis B virus carriers at a single time point evaluation.
Maimone S; Caccamo G; Squadrito G; Alibrandi A; Saffioti F; Spinella R; Raffa G; Pollicino T; Raimondo G
Liver Int; 2017 Mar; 37(3):362-368. PubMed ID: 27606573
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification for hepatitis B virus related hepatocellular carcinoma.
Lin CL; Kao JH
J Gastroenterol Hepatol; 2013 Jan; 28(1):10-7. PubMed ID: 23094699
[TBL] [Abstract][Full Text] [Related]
19. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
Demirören K; Kocamaz H; Doğan Y
Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
[TBL] [Abstract][Full Text] [Related]
20. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
